Analysts Issue Forecasts for PVLA FY2024 Earnings

Palvella Therapeutics (NASDAQ:PVLA) – Research analysts at HC Wainwright issued their FY2024 EPS estimates for shares of Palvella Therapeutics in a report issued on Thursday, December 26th. HC Wainwright analyst A. Fein forecasts that the company will earn ($4.37) per share for the year. HC Wainwright has a “Buy” rating and a $38.00 price target on the stock.

Separately, Cantor Fitzgerald assumed coverage on Palvella Therapeutics in a research note on Wednesday, December 18th. They issued an “overweight” rating on the stock.

Palvella Therapeutics Trading Up 1.0 %

Shares of PVLA opened at $12.00 on Monday. Palvella Therapeutics has a 12-month low of $6.20 and a 12-month high of $22.32. The firm has a market cap of $15.84 million, a PE ratio of -0.99 and a beta of 0.61.

Insider Activity at Palvella Therapeutics

In other Palvella Therapeutics news, Director George M. Jenkins bought 4,000 shares of Palvella Therapeutics stock in a transaction that occurred on Wednesday, December 18th. The stock was acquired at an average cost of $12.93 per share, for a total transaction of $51,720.00. Following the completion of the transaction, the director now directly owns 180,671 shares in the company, valued at $2,336,076.03. This represents a 2.26 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. 6.39% of the stock is currently owned by corporate insiders.